Benzinga | Jan 21, 2022 07:01AM EST

B of A Securities Upgrades Acumen Pharmaceuticals to Buy, Lowers Price Target to $14

B of A Securities analyst Geoff Meacham upgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Neutral to Buy and lowers the price target from $16 to $14.